ALSO NOTED: Depomed surges on new data; FDA OKs Biomira study; and much more...

> Shares of Depomed surged on the news that a Phase II trial has produced data that demonstrates significantly reduced pain scores for patients taking one of two doses of its Gabapentin GR painkiller. Report

> Biomira and the FDA have agreed on a clinical trial design to test Stimuvax for advanced lung cancer. Report

> Genentech announced that an interim analysis shows that a randomized Phase III clinical study of Avastin in combination with interferon alfa-2a therapy in patients with first-line metastatic renal cell carcinoma met the primary analysis endpoint by significantly improving progression-free survival compared to interferon alfa-2a therapy alone. Report

> Alnylam Pharmaceuticals is selling 4.7 million common shares. Report

> Gloucester Pharmaceuticals has released interim data for romidepsin, its histone deacetylase inhibitor. Release

> Newly-launched London Genetics plans to facilitate partnerships between industry and academic centers of excellence in genetics and genomics-based research across London. Release

And Finally… Scientists have been making progress in developing new tests that can detect Alzheimer's at an early stage. Article

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.